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Background: The burden associated with Alzheimer’s disease is 
recognized as one of the most pressing issues in healthcare. This 
study aimed to examine the global and regional burden of Alzheimer’s 
disease and related dementias. 
Methods: Epidemiological data from the latest Global Burden of 
Disease (GBD) dataset were analysed to determine the prevalence, 
incidence and mortality rates from 1990 to 2019 for 204 countries and 
world regions. This dataset derives estimates for health metrics by 
collating primary data from research studies, disease registries and 
government reports. Temporal forecasting was conducted using the 
GBD Foresight tool. 
Results: An estimated 0.7% of the global population has dementia, 
translating to 51.6 million people worldwide. The total number of 
persons affected has more than doubled from 1990 to 2019. 
Dementia metrics showed a continuous increase in prevalence, 
incidence, mortality, and disability adjusted life years (DALYs) rates 
worldwide during the last three decades. Japan has the highest 
prevalence (3,079 cases per 100,000), followed by Italy, Slovenia, 
Monaco, Greece and Germany. The prevalence is higher in high-
income regions such as Western Europe compared to Asia and Africa. 
However, total number of affected individuals is substantial in South 
and East Asian regions, in particular China, Japan and India. Dementia 
related deaths are projected to increase from the current 2.4 million 
per year to 5.8 million by 2040. Women are more likely to be affected 
by dementia than men. Age-standardized rates have not changed 
indicating possible stability of risk factors. 
Conclusions: Alzheimer’s disease and other dementias are rising 
rapidly and will more than double in mortality burden over the next 20 
years. The tremendous burden in high- and middle-income countries 
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can potentially overwhelm communities and health systems. Urgent 
measures are needed to allocate funding and provide residential care 
for affected persons.
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Introduction
Dementia remains one of the leading causes of morbid-
ity and mortality worldwide1. The condition exerts a profound 
negative impact on families, communities and health care 
systems alike2. The World Health Organization (WHO) estimates 
that there are 10 million new cases of dementia each year3. 
Hence, the financial implication of the condition—arising from 
both the direct medical and social care costs as well as the cost 
of informal care—is equivalent to 1.1% of the global gross 
domestic product (GDP)4. Those affected by dementia and 
their informal caregivers also face difficulties and suffer poor 
health outcomes that are persistent5,6. People living with demen-
tia and their informal caregivers are more likely to be diagnosed 
with comorbidities and subsequently experience poorer access 
to health and social care services when compared to their 
unaffected counterparts7,8. Research also demonstrates that 
people living with dementia are disproportionately more 
likely to report a poor quality of life9. This reduced quality of 
life and other inequalities in outcomes are recognized to be 
driven by factors such as economic hardship and social isola-
tion that are ultimately caused by the stigma associated with this 
condition10. Thus, those affected represent a vulnerable 
population group that could be better served by changes within 
healthcare and social services systems.
The burden associated with Alzheimer’s disease is now 
recognized as one of the most pressing issues in the field of 
public health. There is an urgent need for health care systems 
to identify novel and innovative solutions to meet the needs. 
The World Health Assembly (WHA) recently endorsed the 
“Global action plan on the public health response to dementia 
2017–2025,” calling for renewed efforts to increase aware-
ness, research and innovation to tackle this urgent public health 
issue3. However, an effective response to the challenges aris-
ing from dementia first requires an accurate understanding of 
the patterns of prevalence and burden of dementia11,12.
The aim of this study was to analyse the global and regional 
burden as well as trends and forecasts for Alzheimer’s 
disease and related dementias. As a unique contribution, this 
study assessed yearly trends using age-standardized rates to 
control for the effect of population aging.
Methods
Data source
Based on the aim of study, the inclusion criteria for data 
included prevalence, incidence, mortality rates of demen-
tia for global, regional and national levels. Exclusion criteria 
included subnational data such as hospital-based records and 
neurological diseases other than dementia such as Parkinson’s 
disease and stroke. We extracted health metrics on dementia 
from the Global Burden of Disease (GBD) dataset. GBD is the 
largest and most up-to-date repository of epidemiological data 
for any given condition including dementia13. GBD 2019 
release has data on 204 countries for 286 causes of death. The 
robustness of this dataset stems from its reliance on a wide 
range of primary sources, independent research studies, 
government reports, vital registration, verbal autopsies, disease 
registries, healthcare projects and census data. GBD 2019 uti-
lized 990 primary data sources related dementia to develop its 
estimates. Based on statistical modelling from these data sources, 
GBD produces reliable estimates of health metrics. Further-
more, GBD incorporates modelling adjustment to address data 
sampling issues, missing data and variations in case defini-
tion. The methods used are compliant with Guidelines for 
Accurate and Transparent Health Estimates Reporting (GATHER 
statement).
Data variables
Health metrics analysed in the present study included preva-
lence, incidence, mortality and disability-adjusted life years 
(DALY). DALY is a better measure of human suffering from a 
disease than prevalence or mortality, as it combines years lived 
with disability and the years of life lost due to premature death. 
Data for dementia were obtained from GBD using the Results 
tool. Dementia is listed under Neurological Disorders in GBD 
and coded as B.5.1 Alzheimer’s disease and other dementias. 
Data visualization was conducted in Microsoft Excel 2016 as 
well as the GBD Compare tool. Sub-classification of dementias 
such as vascular, frontotemporal and dementia with Lewy 
bodies was not available in this dataset. Epidemiological data 
on mild cognitive impairments was not included in the GBD.
Data analysis
Data were analysed using GBD analytical tools including 
visualizations and forecasting. These tools were utilized in 
order to achieve the highest fidelity. We analysed both raw and 
age-adjusted rates of dementia prevalence and incidence. 
Age-standardized rates remove the effect of population age across 
countries as well as over time, thus enabling inferences about 
intrinsic changes in dementia burden. Age of onset of demen-
tia was inferred from age-specific incidence rates. We sought 
to assess whether the age of onset was decreasing over time 
by comparing figures from 1990 with those from 2019. Fore-
casting for projections for the next 20 years was achieved using 
the GBD Foresight tool, with the following settings: scenario: 
reference; uncertainty: off; rank: off; and age: all ages (unstand-
ardized). Statistical data analysis was conducted using SPSS 
version 26 (IBM Inc., Armonk, NY, 2019). Paired samples 
t-tests were used to compare differences in prevalence rates across 
gender and to evaluate changes in incidence rates over from 




The global prevalence of dementia was 0.69% [uncertainty inter-
val (UI); 0.59, 0.79] of the world population in 2019 (Table 1). 
The total number of persons affected has more than doubled 
from 1990 to 2019: increasing from 20.5 million to 51.6 million 
[UI; 44.2, 59.0 million] globally. The worldwide prevalence rate 
for all forms of dementia was 667.2 cases per 100,000 persons 
[UI; 572.2, 762.8]. In comparison to other major neurological 
diseases, the prevalence of dementia was considerably higher. For 
example, the prevalence of Parkinson’s disease was 110 cases, 
and multiple sclerosis 22.7 cases per 100,000 persons. Women 
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Table 1. Burden of Alzheimer’s disease and other dementias.
Region Prevalence 
(cases per 100,000 
population)






Global average 667 327 51,624,000
Europe 1,443 689 12,251,000
        Russia 1,150 515 1,686,000
        Germany 1,864 836 1,582,000
        Italy 2,270 1,110 1,369,000
        France 1,698 881 1,124,000
        United Kingdom 1,241 651 834,000
Asia 598 297 27,230,000
        China 924 420 15,299,000
        Japan 3,079 1,613 4,579,000
        India 266 153 4,249,000
        South Korea 1,119 537 685,000
        Iran 559 271 542,000
Americas 938 439 9,474,000
        United States 1,495 618 4,902,000
        Canada 1,459 666 532,000
        Mexico 430 272 537,000
        Brazil 786 395 1,702,000
        Argentina 839 393 378,000
Africa 197 108 2,591,000
        South Africa 381 192 211,000
        Nigeria 124 84 266,000
        Egypt 299 137 295,000
        Algeria 461 228 193,000
        Morocco 485 240 174,000
Notes: selected countries shown in this table (all countries were included in the analysis). Data 
from Global Burden of Disease, 2019. DALY, disability-adjusted life years.
were more likely to be affected by dementia than men. For 
instance, among persons over the age of 80, the prevalence rate 
among women was 20,244 per 100,000 [UI; 16,661, 34,236] 
compared to 14,378 per 100,000 [UI; 11,667, 17,478] in men.
Across regions, high-income Asia Pacific had the highest 
prevalence followed by Europe, Austrasia and North America 
(Figure 1). South Asia and Africa ranked the lowest in terms of 
prevalence of dementia. The highest prevalence rates in descend-
ing order were: Japan (3,079 cases per 100,000 population), 
Italy (2,269 cases per 100,000), Slovenia (1,963 cases), Monaco 
(1,962 cases), Greece (1,874 cases), and Germany (1,863 cases 
per 100,000). In terms total number persons living with demen-
tia, China (13.1 million cases), United States (4.9 million), 
Japan (3.9 million), India (3.6 million) and Brazil (1.7 million) 
have the highest burden in the world.
Trends
Dementia metrics showed a continuous increase in preva-
lence, incidence, mortality, and disability adjusted life years 
(DALYs) rates worldwide during the 29 years of estimates from 
1990 to 2019. Certain regions, such as Western Europe, showed 
a faster rate of rise than the global average. Japan, in particu-
lar, experienced a marked increase in prevalence rates, from 
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Figure 1. Global burden of Alzheimer’s disease and other dementias. Notes: prevalence rates per 100,000 population by country. Red, 
orange and yellow shades indicate higher prevalence. Source: Global Burden of Disease, 2019.
772 cases per 100,000 population in 1990 to 3,079 per 
100,000 in 2019. Thus, the total number of cases continued 
to rise with population growth and aging.
As prevalence rates are affected by the proportion of 
elderly in a population, we used age-standardized rates to 
aid in comparisons between countries. Age standardization 
adjusts for any differences in underlying population age 
distributions. After age-standardization (to control for the 
effect of population aging), incidence and prevalence rates 
appeared to remain stable during the same period (Figure 2). 
Hence, there appeared to be no intrinsic increase in rates of 
dementia after controlling for population aging.
Age of onset
The age distribution of new cases showed incidence starting 
from the latter half of the fifth decade of life. The age distribu-
tion of new cases of dementia has not changed since 1990 
(Figure 3A). As expected, the incidence was highest at older 
ages (Figure 3B).
Mortality
Mortality rates have been rising rapidly and continuously since 
1990. The global death rate due to dementia increased from 
10.49 deaths per 100,000 in 1990 to 20.98 deaths per 100,000 
in 2019 [UI; 5.27, 54.36]. Statistical forecasting showed a 
rising rate reaching 66.4 deaths per 100,000 [UI; 51.6, 85.2] by 
2040. Most regions are forecasted to continue to follow this 
rising trend over the next 20 years. The highest death rates due 
to dementia are expected in Japan at 265 deaths per 100,000 
population by 2040. Total deaths due to dementia are projected 
to increase from the current 2.4 million per year to 
5.8 million by 2040 [UI; 4.5, 7.5 million].
Discussion
This study adds important insights on the global burden of 
dementia and its predicted trajectory. Based on the latest data 
from GBD, three key findings have emerged from our analy-
sis. The incidence of dementias is rising especially in Western 
Europe and Japan. A large burden of dementia (total number 
of cases) was present in developing countries. When standard-
ized for population aging, the rates are stable. These findings 
have considerable implications for the health and social care 
sectors, which need to adapt and prepare in advance to 
meet the rising demand.
The burden arising from Alzheimer’s disease and other 
dementias is acknowledged to be markedly high when com-
pared to other non-communicable conditions affecting older age 
groups14. The associated burden of care correlates with the sever-
ity of dementia as the subsequent cognitive and functional 
decline negatively impacts the affected individual’s ability 
to be independent and engage in activities of daily living15,16. 
These factors combined with rising prevalence rates due to 
population growth and aging as well as the absence of curative 
therapies forecast a bleak picture of the future. It is not 
surprising that dementia has now become the focus of public 
health policy and research16–18.
Japan depicts a grim case study of the social burden of demen-
tia. Our analysis revealed a rapid increase in prevalence and 
mortality rates from 1990 to 2019, and a forecasted meteoric 
rise over the next two decades. The proportion of Japanese 
people over the age of 65 is now 26.7%19. Consequently, meet-
ing the healthcare demands of the aging population has become 
a public health priority. However, the rising demand can 
easily overwhelm healthcare and social services capacity20. 
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Figure 2. Trends in the burden of dementia. (a) Incidence (unadjusted rates). (b) Age-standardized incidence.
The number of residential care homes in Japan for people 
living with dementia remains suboptimal and the accessible 
care available is provided in hospital settings16–18. Hospital envi-
ronments have long been considered inappropriate for long-term 
care of those affected. These issues raise serious concerns about 
how countries such as Japan and those in Western Europe will 
meet this ever-increasing burden of dementia, perhaps repre-
senting the greatest challenge for their current and future health 
care systems. On the other hand, it is important to recognize that 
the lower prevalence rates of dementia found in certain regions 
such as South Asia may arise from lack of accessible healthcare 
services. All forms of dementia are underdiagnosed21. Amongst 
other factors, the lack of accessible health care may impede 
timely recognition18,19.
A novel finding emerging from our analysis is the stability of 
age-standardized rates. This implies that (apart from age) risk 
factors for dementia have remained constant over the last three 
decades. The stability of age-standardized prevalence rates 
over time may be a reflection of age continuing to represent 
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Figure 3. Age distribution of dementia. (a) Prevalence (per 100 persons) by gender. p = .059, paired samples t-test, comparing prevalence 
in each age group for males and females. (b) Incidence (age of onset of new cases) change over three decades. p = .33, paired samples 
t-test, comparing incidence in each age group for 1990 and 2019.
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the strongest predictor of dementia22. Epidemiological studies 
exploring the relationship between age and dementias have 
found that the rate of cognitive decline is 10 times greater during 
the last three years of life, irrespective of the country of 
residence22. Potential risk factors such as diabetes, hypertension, 
smoking, sedentary lifestyle and obesity are rising globally, and 
yet are not reflected in age-standardized rates of dementia. The 
reasons for this remain unresolved. Insights from certain stud-
ies indicate that obesity affects dementia selectively23. A national 
registry-based study from Denmark indicated a steady decline 
incidence since 200324. These results have not been consistently 
reported in other regions. It is possible that improvements in 
dietary intake, physical activity level and reductions in 
tobacco consumption may contribute to these remarkable 
trends25.
This study is subject to a few limitations. Country-level 
comparisons are generalizations that are susceptible to eco-
logical bias. The GBD dataset relies on multiple sources that 
adopt heterogeneous methodologies including varying case 
definitions, which can make comparisons less robust. However, 
statistical modelling techniques employed by GBD adjust for 
these potential sources of error. At present, GBD provides the 
most comprehensive and current data available on the burden of 
dementia.
Conclusions
Dementia now represents one of the most pressing issues 
facing global public health resulting in a burden of care that 
profoundly impacts families, communities, and healthcare 
systems alike. Our findings can be used to inform policies and 
global health agendas that direct the allocation of resources with 
a need to address and support specific subgroups and regions. 
Research is needed to identify mild cognitive impairment and 
early markers of disease progression26. Future research needs 
to explore differences in prevalence rates of the various forms 
of dementia and the associated care burden. There remains an 
urgent need for public health initiatives that aim to promote 
healthier living among older populations in recognition of 
the many risk factors now associated with the development 
of dementia. Otherwise, several countries provide a stark 




The data used in this study was obtained from the Institute 
of Health Metrics and Evaluation, University of Washington. 
http://ghdx.healthdata.org/ihme_data. The search term used 
was: B.5.1 Alzheimer’s disease and related dementias.
Data are available under the terms of the Open Data Commons 
Attribution License.
Underlying data
Open Science Foundation: Dementia. https://doi.org/10.17605/
OSF.IO/DYBTM27.
This project contains the following underlying data:
-    Supplementary Appendix – Dementia 2019 data (numeric 
estimates for prevalence, incidence, mortality and DALYs)
Reporting guidelines
Open Science Foundation: GATHER checklist for ‘Epidemiol-
ogy of Alzheimer’s disease and other dementias: rising global 
burden and forecasted trends’. https://doi.org/10.17605/OSF.IO/
DYBTM27.
Data are available under the terms of the Creative Commons 
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). 
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